

ACORDA THERAPEUTICS INC Reported by BAB BIO VENTURES LLP

FORM 3

(Initial Statement of Beneficial Ownership)

Filed 12/16/03 for the Period Ending 12/17/03

Address 420 SAW MILL RIVER ROAD

ARDSLEY, NY 10502

Telephone 914-347-4300

CIK 0001008848

Symbol ACOR

Fiscal Year 12/31





UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Pe	g Person 2. Date of Event Requiring Statement (MM/DD/YYYY) 12/17/2003			3. Issuer Name and Ticker or Trading Symbol ACORDA THERAPEUTICS INC [ACRD]				
(Last) (First) (Middle)	4. Relations	ship of Reporti	ng Person(s)	to Issuer (Che	eck all applica	able)		
111 Huntington Avenue, 31st Floor	Officer	Director Officer (give title below)		X 10% Owner Other (specify below)				
(Street) Boston,MA 02199 (City) (State) (Zip	Original Fi	5. If Amendment, Date Original Filed (MM/DD/YYY)		6. Individual or Joint/Group Filing (Check Applicable Line) Y) Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person				
	Table I - N	on-Derivative	Securities B	eneficially O	wned			
1.Title of Security (Instr. 4)		2. Amount	2. Amount of Securities 3. Beneficially Owned Ownersh		4. Natur Owners irect (Instr. 5	4. Nature of Indirect Beneficial Ownership		
Table II - Derivative S	ecurities Benefic	cially Owned (e.g., puts, c	alls, warrant	s, options, co	onvertible se	ecurities)	
1. Title of Derivate Security (Instr. 4)	2. Date Exerci Expiration Da (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative	Ownership Beneficial	Ownership	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)		
Series E Preferred Stock	12/23/2003	12/23/2003	Common Stock	7249058 (2)	\$0.00 (1)	D		
Series E Preferred Stock	12/23/2003	12/23/2003	Common Stock	662171 (3)	\$0.00 (1)	I	See Footnotes 2 and 3	
Series H Preferred Stock	12/23/2003	12/23/2003	Common Stock	88534 (2)	\$0.00 (1)	D		
Series H Preferred Stock	12/23/2003	12/23/2003	Common Stock	13195 (4)	\$0.00 (1)	I	See Footnotes 2 and 4	
Series I Preferred Stock	12/23/2003	12/23/2003	Common Stock	1947514 (2)	\$0.00 (1)	D		

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)							
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	Ownership
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Security Direct (D) or Indirect (I) (Instr. 5)	
Series I Preferred Stock	12/23/2003	12/23/2003	Common Stock	319675 (5)	\$0.00 (1)	I	See Footnotes 2 and 5
Series J Preferred Stock	12/23/2003	12/23/2003	Common Stock	13587598	\$0.00 (1)	D	
Series J Preferred Stock	12/23/2003	12/23/2003	Common Stock	1718523 (6)	\$0.00 (1)	I	See Footnotes 2 and 6

Explanation of Responses:

- The Issuer's Preferred Stock will automatically convert into Common Stock upon the closing of the Issuer's initial public offering. The number of shares does not reflect the automatic conversion of each share of Preferred Stock into one share of Common Stock upon the closing of the initial public offering.
 - The shares are held by BB BioVentures, L.P. ("BB BioVentures"), who is under common control with MPM BioVentures Parallel Fund, L.P. ("MPM Parallel") and MPM Asset Management Investors 1998 LLC ("MPM Asset"). BAB BioVentures L.P. ("BAB BV") and BAB BioVentures NV ("BAB NV") are the direct and indirect general partners of BB BioVentures. MPM BioVentures I L.P.
- (2) ("BioVentures LP") and MPM BioVentures I LLC ("Bioventures LLC") are the direct and indirect general partners of MPM Parallel. Luke Evnin ("LE"), Ansbert Gadicke ("AG") and Michael Steinmetz ("MS") are the managers of BAB NV, MPM Asset and BioVentures LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (3) The shares are held as follows: 90,979 by MPM Asset and 571,192 by MPM Parallel.
- (4) The shares are held as follows: 1,170 by MPM Asset and 12,025 by MPM Parallel.
- (5) The shares are held as follows: 26,074 by MPM Asset and 293,601 by MPM Parallel.
- (6) The shares are held as follows: 176,020 by MPM Asset and 1,542,503 by MPM Parallel.

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
BB BIOVENTURES L P					
111 Huntington Avenue		x			
31st Floor		Λ			
Boston, MA 02199					
BAB BIO VENTURES LLP					
111 Huntington Avenue		x			
31st Floor		Λ			
Boston, MA 02199					
BAB BIO VENTURES NV					
111 Huntington Avenue		x			
31st Floor		Λ			
Boston, MA 02199					
MPM ASSET MANAGEMENT INVESTORS					
1998 LLC/MA					
111 Huntington Avenue		X			
31st Floor					
Boston, MA 02199					
MPM BIO VENTURES PARALLEL FUND L P					
111 Huntington Avenue		X			
31st Floor					
Boston, MA 02199					

Signatures By Luke Evnin, manager of BAB BioVentures NV, the general partner of BAB BioVentures L.P., the general partner of BB BioVentures L.P. /s/ Luke Evnin	12/16/2003
** Signature of Reporting Person	Date
By Luke Evnin, manager of BAB BioVentures NV, the general partner of BAB BioVentures L.P. /s/ Luke Evnin	12/16/2003
** Signature of	Date

Reporting Person

MPM BIO VENTURES I LP		1 1	
111 Huntington Avenue	l x		
31st Floor	Α		
Boston, MA 02199			
MPM BIO VENTURES I LLC			
111 Huntington Avenue	l x		
31st Floor	A		
Boston, MA 02199			
GADICKE ANSBERT			
111 Huntington Avenue	l x		
31st Floor	Α		
Boston, MA 02199			
EVNIN LUKE			
111 HUNTINGTON AVENUE	l x		
31ST FLOOR	Α		
BOSTON, MA 02199			

By Luke Evnin, manager of BAB BioVentures NV /s/ Luke Evnin	12/16/2003
** Signature of Reporting Person	Date
By Luke Evnin, manager of MPM Asset Management Investors 1998 LLC /s/ Luke Evnin	12/16/2003
** Signature of Reporting Person	Date
By Luke Evnin, manager of MPM BioVentures I LLC, the general partner of MPM BioVentures I L.P., the general partner of MPM BioVentures Parallel Fund, L.P. /s/ Luke Evnin	12/16/2003
** Signature of Reporting Person	Date
By Luke Evnin, manager of MPM BioVentures I LLC, the general partner of MPM BioVentures I L.P. /s/ Luke Evnin	12/16/2003
** Signature of Reporting Person	Date
By Luke Evnin, manager of MPM BioVentures I LLC /s/ Luke Evnin	12/16/2003
** Signature of Reporting Person	Date
/s/ Luke Evnin	12/16/2003
** Signature of Reporting Person /s/ Ansbert	Date 12/16/2003
Gadicke	Date
Signature of Reporting Person	Duc

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

End of Filing



© 2005 | EDGAR Online, Inc.